Dabrafenib is a potent selective small-molecule inhibitor of BRAF kinase that is orally bioavailable and FDA-approved for treating multiple cancers with activated BRAF (BRAF V600E or V600K mutations) such as melanoma, small cell lung carcinoma, thyroid, and biliary tract cancers (15–18). This evidence concerns the gene BRAF and thyroid gland disorder.